Paperonium

← Back to the plain-language case

Abstract reports Table 2's other-respiratory-infection hazard ratios as the COVID-19 severity and mortality estimates

eLife (2024) Β· doi:10.7554/eLife.94973 Β· PMC11251724

Summary

This UK Biobank cohort study (160,923 participants) relates regular proton pump inhibitor (PPI) use to respiratory infections. Its abstract gives the hazard ratios for severe COVID-19 and COVID-19 mortality as 1.19 (95% CI 1.11–1.27) and 1.37 (1.29–1.46). Those two triplets match, digit for digit, the fully adjusted Table 2 estimates for other upper and other lower respiratory infections. The paper's Results text and Supplementary file 1e report the COVID-19 outcomes as 1.33 (1.09–1.61) and 1.46 (1.05–2.03). The paper's p-values, event counts and severity E-value fit the Results figures and not the abstract's. The direction and significance stay the same, but the abstract understates both effects and makes the two estimates look far more precise than they are: its intervals are 2.9 and 5.3 times too narrow on the log scale. The error has been in every version since the 2022 preprint, and as of 2026-10-24 no correction has been published.

What the paper reports

Abstract, Results:

In contrast, the risk of COVID-19 infection was not significant with regular PPI use (HR 1.08, 95% CI 0.99–1.17), while the risks of severe COVID-19 (HR 1.19. 95% CI 1.11–1.27) and mortality (HR 1.37. 95% CI 1.29–1.46) were increased.

Results, "Proton pump inhibitor use and other respiratory infections, COVID-19 severity, and COVID-19 mortality":

For other upper and lower respiratory infections, the risks among regular PPI users were increased by 19% (aHR 1.19, 95% CI 1.11–1.27, p<0.001; e-value 1.67) and 37% (aHR 1.37, 95% CI 1.29–1.46, p<0.001; e-value 2.08), respectively. In contrast, the risks of developing severe COVID-19 (aHR 1.33, 95% CI 1.09–1.61, p=0.004; e value 1.99) and mortality due to COVID-19 (aHR 1.46, 95% CI 1.05–2.03, p=0.024; e value 2.03) were significantly increased among PPI users compared to those among PPI non-users (Supplementary file 1e).

Table 2, regular PPI use rows. The columns are Case/person-years | non-adjusted HR (95% CI) | p | age/sex-adjusted HR (95% CI) | p | fully adjusted HR (95% CI) | p:

Other upper respiratory infections: Regular PPI use | 1 118/3 988 | 1.30 (1.22–1.38) | <0.001 | 1.31 (1.23–1.39) | <0.001 | 1.19 (1.11–1.27) | <0.001

Other lower respiratory infections: Regular PPI use | 1 486/5 598 | 1.78 (1.67–1.88) | <0.001 | 1.65 (1.56–1.74) | <0.001 | 1.37 (1.29–1.46) | <0.001

Supplementary file 1e, "Associations of PPI use with COVID-19 severity and mortality", regular PPI use rows (same column layout):

COVID-19 severity: Regular PPI use | 138/100 | 2.32 (1.94-2.77) | <0.001 | 1.95 (1.64-2.34) | <0.001 | 1.33 (1.09-1.61) | 0.004

COVID-19 mortality: Regular PPI use | 48/36 | 2.61 (1.93-3.54) | <0.001 | 1.90 (1.40-2.58) | <0.001 | 1.46(1.05-2.03) | 0.024

The matching non-regular-use rows have 1 104 and 337 cases.

Methods, "Definition of outcomes":

The secondary outcomes included other upper or lower respiratory infections, COVID-19 mortality, and COVID-19 severity.

Severe COVID-19 cases were defined as being hospitalized for COVID-19. COVID-19 mortality was defined as the underlying recorded cause of death due to COVID-19 (ICD-10 U07.1 and U07.2).

Abstract, Conclusions, and Discussion, "Conclusion":

PPI users are associated with increased risks of influenza, pneumonia, as well as COVID-19 severity and mortality compared to non-users, while the effects on pneumonia or COVID-19-related outcomes under PPI use were attenuated when compared to the use of H2RAs.

In conclusion, compared to non-users, people regularly taking PPIs are associated with increased susceptibility to influenza, pneumonia, as well as COVID-19 severity and mortality, while their association with pneumonia and COVID-19-related outcomes is diminished after comparison with H2RA use and remains to be further explored.

What the paper's own numbers show

Method. I compared each hazard ratio and confidence interval in the abstract with every fully adjusted row of Table 2, and with every COVID-19 severity and mortality estimate in Supplementary file 1. That covers table 1e (all three models), 1j (multiple imputation), 1m (propensity-score matched) and 1n (versus H2RA users). I treated each 95% CI as a Wald interval, symmetric on the log-HR scale as Cox output is, so SE = (ln U βˆ’ ln L)/(2 Γ— 1.96) and p = 2[1 βˆ’ Ξ¦(|ln HR|/SE)]. I recomputed each E-value from its point estimate as E = HR + √(HR(HR βˆ’ 1)), which is the formula the paper's other printed E-values follow. To check how plausible each interval's width is, I compared its SE with √(1/d₁ + 1/dβ‚€), where d₁ and dβ‚€ are the event counts in the two groups. This is the approximate information-based SE of a log hazard ratio for a binary exposure, and covariate adjustment usually makes the actual SE larger, not smaller. recompute.py.txt prints every number below.

Quantity Location Reported Recomputed from the paper's numbers
Severe COVID-19, HR (95% CI) Abstract 1.19 (1.11–1.27) Identical to Table 2, other upper respiratory infections, fully adjusted
COVID-19 mortality, HR (95% CI) Abstract 1.37 (1.29–1.46) Identical to Table 2, other lower respiratory infections, fully adjusted
Severe COVID-19, aHR (95% CI) Results text; Supp. 1e 1.33 (1.09–1.61) Differs from the abstract
COVID-19 mortality, aHR (95% CI) Results text; Supp. 1e 1.46 (1.05–2.03) Differs from the abstract
Any other COVID-19 severity or mortality estimate equal to the abstract's values Supp. 1e (non- and age/sex-adjusted), 1j, 1m, 1n; Table 2 COVID-19 positivity (3 models) β€” None
Influenza, pneumonia, COVID-19 positivity HRs Abstract vs Table 2 1.32 (1.12–1.56); 1.42 (1.26–1.59); 1.08 (0.99–1.17) Identical to Table 2 (the other abstract estimates are transcribed correctly)
Severe COVID-19: p from CI Results p = 0.004 0.0042
COVID-19 mortality: p from CI Results p = 0.024 0.0244
Severe COVID-19: E-value Results 1.99 1.99 for HR 1.33 (1.67 for HR 1.19)
COVID-19 mortality: E-value Results 2.03 2.28 for HR 1.46 (2.08 for HR 1.37); 2.03 corresponds to HR 1.347, nearer 1.37 than 1.46; it supports neither figure and is a separate minor inconsistency
E-values for influenza, pneumonia, other upper, other lower (Table 2 HRs) Results 1.97, 2.19, 1.67, 2.08 1.97, 2.19, 1.67, 2.08
E-values vs H2RA: influenza, other upper, other lower Results 2.87, 1.88, 1.99 2.87, 1.88, 1.99
Severe COVID-19: SE(ln HR) Abstract vs Results β€” 0.0344 vs 0.0995 (ratio 2.90)
COVID-19 mortality: SE(ln HR) Abstract vs Results β€” 0.0316 vs 0.1682 (ratio 5.33)
CI width on the HR scale Abstract vs Results 0.16 vs 0.52; 0.17 vs 0.98 ratios 3.25 and 5.76
Event-based SE, severe COVID-19 (138 / 1 104 events) Supp. 1e β€” 0.0903. Results SE is 1.10 Γ— this; abstract SE is 0.38 Γ— this
Event-based SE, COVID-19 mortality (48 / 337 events) Supp. 1e β€” 0.1543. Results SE is 1.09 Γ— this; abstract SE is 0.20 Γ— this
Event-based SE, other upper (1 118 / 14 449) and other lower (1 486 / 14 494) Table 2 β€” 0.0310 and 0.0272. The abstract SEs (0.0344, 0.0316) are 1.11 Γ— and 1.16 Γ— these
Excess hazard, 100 Γ— (HR βˆ’ 1) Abstract vs Results 19% and 37% 33% and 46%
All four intervals exclude HR = 1 Abstract and Results β€” Yes
Separate minor point: COVID-19 mortality vs H2RA users, p from CI Supp. 1n; Results 0.83 (0.45–1.56), p = 0.745 p = 0.557 (0.539–0.574 within 2-decimal rounding); not significant either way

Four independent features of the paper point to the Results figures and away from the abstract. First, the HR and both CI limits of each abstract value match a different outcome's row exactly. Second, the printed p-values (0.004, 0.024) are those of the Results intervals. Third, the printed severity E-value (1.99) is that of HR 1.33, not of HR 1.19 (1.67, which the paper itself prints for the other upper respiratory row). Fourth, the abstract's interval widths are not attainable with 138 and 48 events. They need SEs of about 0.03, which is what roughly 1,100–1,500 events give, and those are the event counts of the two Table 2 rows they match. The printed mortality E-value (2.03) does not help decide the question. It matches neither HR 1.46 (2.28) nor HR 1.37 (2.08); it corresponds to HR 1.347, slightly nearer the abstract's 1.37 than the Results' 1.46. It is therefore treated as a separate minor inconsistency, not as evidence either way.

Figure

Abstract COVID-19 estimates beside the Table 2 rows they match and the Results/Supplementary file 1e COVID-19 estimates

Figure 1. The left panel shows the two COVID-19 estimates printed in the abstract (orange circles). The right panel shows the fully adjusted Table 2 rows for other upper and other lower respiratory infections, and the fully adjusted severe-COVID-19 and COVID-19-mortality estimates in the Results text and Supplementary file 1e (blue squares), each with the E-value printed in the Results. The Table 2 rows carry the same orange marker as the abstract because their numbers are identical to the abstract's. Solid orange connectors join each abstract value to the Table 2 row with identical numbers but a different outcome. Dashed blue connectors join it to the estimate for the same outcome, which has different numbers. The printed severity E-value (1.99) follows the right-hand estimate. The asterisk marks the printed mortality E-value (2.03), which matches neither HR 1.46 (recomputed 2.28) nor HR 1.37 (2.08) and so supports neither figure. All numbers are printed in the paper or by recompute.py.txt. The paper's own figures are not reproduced.

Hazard ratios and 95% CIs for severe COVID-19 and COVID-19 mortality, as printed in the abstract and in the Results, on a log axis

Figure 2. Hazard ratios for regular PPI use, on a log axis with a reference line at HR = 1. For each COVID-19 outcome, the orange circle and interval are the values printed in the abstract and the blue square and interval are the fully adjusted estimate in the Results text and Supplementary file 1e. The intervals in the Results, based on 138 and 48 events among regular PPI users, are 2.9 and 5.3 times wider on the log scale than the ones in the abstract. All four exclude 1, so the error changes the size and the apparent precision of the associations but not their direction or significance.

Why it matters

The abstract is where most readers, and most citing papers and evidence summaries, take the numbers from. For two of its five reported non-user comparisons, it gives effect sizes that belong to different outcomes. The COVID-19 severity and mortality associations are understated (19% vs 33% and 37% vs 46% excess hazard). More consequentially, they look about three to five times more precise than the data allow: the abstract implies a mortality HR known to within 1.29–1.46, when the 48 deaths among regular users support only 1.05–2.03. In a meta-analysis that took the abstract's figures, the inverse-variance weight of this study's mortality estimate would be inflated by a factor of about 28 (5.33Β²) and that of the severity estimate by about 8 (2.90Β²). Either estimate would then carry far more weight than the data justify.

The qualitative claims survive. All four intervals exclude 1, so "increased" is correct for both outcomes in both places. The conclusions of the abstract and the Discussion, which give no numbers, are unaffected. The comparison with H2RA users (Supplementary file 1n), on which the abstract bases its statement that COVID-19-related risks "were not evident", is a separate analysis and is not involved. Of the non-user comparisons, the influenza, pneumonia and COVID-19 positivity figures in the abstract match Table 2. The error is confined to the two secondary COVID-19 outcomes.

Explanations considered

Status

As of 2026-10-24:

Suggested correction

In the Abstract, Results, replace "while the risks of severe COVID-19 (HR 1.19. 95% CI 1.11–1.27) and mortality (HR 1.37. 95% CI 1.29–1.46) were increased" with "while the risks of severe COVID-19 (HR 1.33, 95% CI 1.09–1.61) and COVID-19 mortality (HR 1.46, 95% CI 1.05–2.03) were increased". These are the fully adjusted estimates in the Results and Supplementary file 1e. The authors may also wish to check two minor points. First, the E-value printed for COVID-19 mortality (2.03), which would be 2.28 for HR 1.46. Second, the p-value in Supplementary file 1n for COVID-19 mortality versus H2RA users (printed 0.745; the printed interval 0.45–1.56 implies about 0.56). Neither changes a conclusion. A typographic slip in Table 2 could be fixed at the same time: the influenza interval is printed as "1.32 (1,12–1.56)".